Lucius Gefitinib – Buy Online
Gefitinib was first approved by the U.S. FDA in 2015 for the treatment of patients with non-small cell lung cancer with specific EGFR mutations.
View Product
AML New Drug | FLT3 Inhibitor Gefitinib: Price and Review Report in China – Moshang Pharma
2026年第6周02.02-02.08全球创新药研发概览 摩熵医药 2026-02-10 2026年第6周02.02-02.08国内医药大健康行业政策法规汇总 摩熵医药 2026-02-10 基于代谢酶和转运体的体外药物相互作用研究概述与案例分析 单晓蕾， 付淑军， 高广花， 孙涛， 王庆利， 余珊珊 国家药品监督管理局药品审评中心 2019-11-01 C…
Main text
Global Innovative Drug R&D Overview (Week 6, 2026, February 2-8) – Moshang Pharmaceuticals (February 10, 2026) Summary of Domestic Pharmaceutical and Healthcare Industry Policies and Regulations (Week 6, 2026, February 2-8) – Moshang Pharmaceuticals (February 10, 2026) Overview and Case Analysis of In Vitro Drug Interaction Studies Based on Metabolic Enzymes and Transporters – Shan Xiaolei, Fu Shujun, Gao Guanghua, Sun Tao, Wang Qingli, Yu Shanshan – Center for Drug Evaluation, National Medical Products Administration (November 1, 2019) Top 10 Global CRO Companies in 2021 – Pharmaceutical Insights (February 26, 2022) Market Insight Center: Pharmaceutical Market Sales Data Analysis, Intelligent Insight, Competitive Landscape Monitoring Acute Myeloid Leukemia (AML) is a highly heterogeneous group of malignant hematologic malignancies. The occurrence and progression of AML are associated with numerous gene mutations, such as FLT3, NPM1, CEBPA, TP53, etc.
Among these, the FLT3 gene is particularly important, as it is the most common gene mutation in AML (FLT3 gene mutation is the most common genetic alteration and poor prognostic factor in acute myeloid leukemia (AML), present in approximately 25-30% of AML patients). Patients with FLT3-mutant AML generally have poor survival. On January 30, 2021, Astellas’ new drug Xospata® (gilteritinib fumarate tablets) was approved by the National Medical Products Administration (NMPA) of China for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations (conditional approval).
Gefitinib received priority review status from the China National Medical Products Administration (NMPA) in July 2020 and was included in the third batch of urgently needed overseas new drugs in November 2020; it took less than 10 months from the submission of its New Drug Application (NDA) in China to its approval. This product was originally jointly developed by Kotobuki Pharmaceuticals and Astellas. Recently, the 2021 edition of the Chinese Society of Hematologic Malignancies (CSCO) guidelines was updated, and novel small-molecule targeted drugs, including FLT3 inhibitors, have brought hope to the treatment of AML patients.
In May 2021, the FLT3 inhibitor gidatetinib was included in the 2021 CSCO guidelines for the treatment of relapsed or refractory AML (non-APL). Analysis of domestic innovative drug/improved new drug clinical trial applications/approval for clinical trials/applications for marketing authorization/approval for marketing authorization. A review of the list of innovative drugs approved by the US FDA in the first half of 2026! Domestic companies BeiGene and Hisun Pharmaceutical are on the list!
A blockbuster BD film worth $1.9 billion!
Sino Biopharmaceutical’s TQC3721 goes global with AstraZeneca, breaking the monopoly of oncology drugs going global. Moshang attends AIBC 2026 | BCPM’s biopharmaceutical data solutions empower the implementation of AI in the pharmaceutical industry. Sino Biopharmaceutical makes a major move: licensing its COPD drug TQC3721 to AstraZeneca for $1.9 billion, and simultaneously securing exclusive rights to two major respiratory drugs from GSK. Overview of global innovative drug R&D (Week 27, 2026, June 29 – July 5). Summary of domestic pharmaceutical and healthcare industry policies and regulations (Week 27, 2026, June 29 – July 5). Analysis of domestic generic drug/biosimilar application/approval data (Week 27, 2026, June 29 – July 5). Analysis of domestic innovative drug/improved new drug clinical trial application/approval/marketing application/marketing approval data (Week 27, 2026, June 29 – July 5). Moxhang Consulting Pharmaceutical Industry Observation Weekly Report (June 29, 2026 – July 5, 2026) July 5, 2026: 28 pages Analysis of the Differences in Business Models between Innovative Drug CROs and Medical Device CROs July 1, 2026: 13 pages June 2026 Global Monthly Report on New Drugs in Development June 30, 2026: 40 pages June 2026 Moxhang Pharmaceutical and Healthcare Investment & Financing & Transaction Monthly Report June 30, 2026: 20 pages June Pharmaceutical Market Hot Topics Review 12411 July 7, 2026: 19:30 2028 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) Overseas February 17, 2028: 02:198143 2028 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Overseas 2028.01.06 01.08 7522 2027 American Society of Clinical Oncology (ASCO) Annual Meeting (Overseas) 2027.06.04 06.08 7553 Good News | Henlius Biotech’s 4 Core Products Included in the 2026 National Essential Medicines List, Continuously Improving Accessibility of High-Quality Biologics 2026-07-10 Authoritative Certification, Moving Forward with Honors | Panlong Qi Tablets Selected for the “National Essential Medicines List (2026 Edition)” 2026-07-10 Although the CRL Issuance is Temporarily Suspended, the FDA is Eliminating “Concerns” 2026-07-10 June 2026 Moshang Pharmaceutical and Healthcare Investment & Financing & Transaction Monthly Report Moshang Consulting 20 2 The Era of Pediatric Drugs:Insights into the Blue Ocean of Innovative Drugs and Project Approval Opportunities Under Policy Breakthroughs (Moshang Consulting) 13 11 Announcement Regarding Drugs and Related Information Passing the Preliminary Formal Review of the 2026 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and Commercial Insurance Innovative Drug Catalog Issuing Authority: National Healthcare Security Administration 2026-06-29 Notice on Publicly Soliciting Opinions Issuing Authority: Center for Drug Evaluation (CDE) 2026-06-25
Products Mentioned in This Article
These products were automatically matched from the article title, summary, and full content.
Lucius Gilteritinib – Buy Online
Gefitinib is a prescription drug approved for marketing in the United States in November 2018. It targets FMS-like tyrosine kinase 3 (FLT3) and its mutations (including FLT3-ITD and FLT3-TKD such as D835Y, I836, etc.). It should be used in strict accordance with the doctor's instructions.
View Product
GILLIDX Gilteritinib 40mg
Gipritinib is a potent, selective, oral FMS-like tyrosine kinase 3 (FLT3) inhibitor. The approval of gipritinib was based on the global, multicenter, open-label, randomized, controlled phase III clinical trial ADMIRAL, which ultimately enrolled 371 patients with relapsed or refractory AML who had FLT3 mutations detected in their blood or bone marrow. These patients were randomized 2:1 to receive either gipritinib or salvage chemotherapy. The primary composite endpoint of the ADMIRAL study was overall survival (OS) and the rate of complete remission (CR/CRh) with complete or partial hematologic recovery. The results of this study were published in the prestigious medical journal *The New England Journal of Medicine* (NEJM).
View Product
ELTROMDX Eltrombopag 50mg
Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.
View Product
ELTROMDX Eltrombopag 25
Eltrombopag is a thrombopoietin receptor agonist that works by inducing the differentiation and proliferation of megakaryocytes (particularly large cells found in the bone marrow). It is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to glucocorticoids, immunoglobulins, or splenectomy. Currently, eltrombopag is approved in more than 100 countries worldwide for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP), and in 43 countries for the treatment of thrombocytopenia in patients with chronic hepatitis C (CHC) to initiate and maintain standard interferon-based therapies for liver disease.
View Product
SALLYDX Selinexor 20mg – Buy Online
Selinexor (ATG-010) was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2019. Selinexor blocks the nuclear export of tumor suppressor, growth regulator, and anti-inflammatory proteins by binding to the nuclear export protein XPO1 (CRM1), promoting the accumulation of these proteins in the cell nucleus and enhancing their anti-cancer activity in cells.
View Product
Frequently Asked Questions
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Gefitinib – Buy Online、Lucius Gilteritinib – Buy Online、GILLIDX Gilteritinib 40mg、ELTROMDX Eltrombopag 50mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
